Merck & Co., Inc. news

   Watch this stock
Showing stories 1 - 10 of about 156   

Articles published

MRK 48.84 -0.54 (-1.09%)
price chart
Give Merck Some Credit For Zepatier
Its potential impact on Merck's top and bottom line has been gravely misunderstood and underestimated. The ingenious of Merck not only in the drug but also in its pricing, timing and marketing. These will have yield lucrative opportunities for Merck ...
One Put, One Call Option To Know About for Merck & Co.
Consistently, one of the more popular stocks people enter into their stock options watchlist at Stock Options Channel is Merck & Co., Inc (Symbol: MRK). So this week we highlight one interesting put contract, and one interesting call contract, from the ...
BTIM Corp. Has $23628000 Stake in Merck & Co., Inc. (MRK)
Merck & Co. logo BTIM Corp. boosted its stake in Merck & Co., Inc. (NYSE:MRK) by 2.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission.
BMO Capital Markets Lowers Merck & Co., Inc. (MRK) Price Target to $58.00  Intercooler Financial
Morningstar Assigns AA Credit Rating to Merck & Co., Inc. (MRK)  Daily Political
Will 2016 Be Merck & Co. Inc.'s Best Year Yet?
Things haven't exactly gotten off on the right foot in 2016 either, with domestic and global concerns weighing further on Merck's stock. Then again, Merck remains healthfully profitable and has tools at its disposal to move the needle. This begs the ...
Merck & Co., Inc: Emend Gets FDA Approval
Merck & Co., (NYSE:MRK) has announced that EMEND´┐Ż (fosaprepitant dimeglumine) in injection formulation has been approved by the U.S.
Merck & Co., Inc. (NYSE:MRK) Gains Approval Of EMEND Injection From The FDA  Journal Transcript
Most Active Healthcare Stocks- Merck & Co. (NYSE:MRK), AstraZeneca (NYSE ...  Seneca Globe
Merck & Co. Inc (MRK) Closes 1.62% Down on the Day for February 08
Dow Jones component Merck & Co. Inc (MRK) saw its stock move -1.62% to $48.58, representing a per-share move of $0.8, on volume of 9.65 million shares for Monday.
Merck & Co., Inc. Falters After Q4 Report
Merck & Co., Inc. (NYSE: MRK) shares are trading lower by $1.65 at $48.76 in Wednesday's session. Despite a Q4 EPS beat of $0.02 with slightly lower revenues, the Street is focusing on its lower FY 2016 outlook for EPS and revenues.
Featured Stock: Merck & Co., Inc.  CWRU Observer
Merck & Co Inc. Announces 4% Rise In Q4 Profit
( - Merck & Co Inc. ( MRK ) reported a profit for its fourth quarter that rose from last year. The company said its bottom line rose to $2.61 billion, or $0.93 per share.
Merck & Co Disappoints on Outlook, Posts Mixed Quarterly Results  Bidness ETC
Shares Of Merck Dip Lower Following Q4 Print  Benzinga
Will Merck and ImmunoGen Provide Breakthrough For Ovarian Cancer?
ImmunoGen Inc. (NASDAQ:IMGN) and Merck & Co. Inc. (NYSE:MRK) have announced that they have started clinical research collaboration for the assessment of ImmunoGen's mirvetuximab soravtansine, in combination with Merck's anti-PD-1 therapy, ...
Merck & Co., Inc. (MRK) to Post Q1 2016 Earnings of $0.82 Per Share, Leerink ...
Merck & Co. logo Merck & Co., Inc. (NYSE:MRK) - Research analysts at Leerink Swann issued their Q1 2016 earnings per share estimates for shares of Merck & Co.